Publications by authors named "Gregoria Lapena"
Article Synopsis
- ATTR amyloidosis is a key cause of heart failure, and research aimed to find connections between cardiac function (measured by global longitudinal strain or GLS), biomarkers, and patient performance.
- In a study involving 13 patients, various echocardiographic assessments, including GLS and a 6-minute walk test, were conducted alongside measuring inflammatory and cardiovascular biomarker levels.
- Results showed significant correlations between GLS and NT-ProBNP, indicating better prognosis with more negative strain values, and that Klotho levels were linked to overall clinical performance in patients with ATTR amyloidosis.
Aims: As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%. The natural evolution of cardiac amyloidosis begins with the deposition of amyloid material in the myocardium, with LVH ensuing at later stages. With current imaging modalities, it is possible to detect TTR cardiac amyloidosis before the hypertrophic stage.
View Article and Find Full Text PDFBackground: Heart failure (HF) with preserved ejection fraction (HFpEF) and monoclonal gammopathy of uncertain significance (MGUS) are two entities that share pathophysiological mechanisms. The aim herein, was to assess the prevalence of MGUS in patients with HFpEF and no left ventricular (LV) hypertrophy, as well as its association with a pre-specified clinical endpoint at 12 months.
Methods: The present study prospectively enrolled 69 patients admitted with HF, with ejection fraction ≥ 50%, and LV wall thickness < 12 mm.